Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022167666 - SARBECOVIRUS BINDERS

Publication Number WO/2022/167666
Publication Date 11.08.2022
International Application No. PCT/EP2022/052919
International Filing Date 07.02.2022
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
CPC
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/52
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
52Constant or Fc region; Isotype
C07K 2317/569
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
C07K 2317/70
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
Applicants
  • VIB VZW [BE]/[BE]
  • UNIVERSITEIT GENT [BE]/[BE]
  • VRIJE UNIVERSITEIT BRUSSEL [BE]/[BE]
Inventors
  • SAELENS, Xavier
  • DE VLIEGER, Dorien
  • ROSSEY, Iebe
  • DE CAE, Sieglinde
  • SEDEYN, Koen
  • VAN SCHIE, Loes
  • EECKHAUT, Hannah
  • FIJALKOWSKA, Daria
  • STORTELERS, Catelijne
  • SCHEPENS, Bert
  • CALLEWAERT, Nico
  • REMAUT, Han
  • NERINCKX, Wim
  • ROOSE, Kenny
  • REITER, Dirk
Agents
  • DE CLERCQ & PARTNERS
Priority Data
21166835.502.04.2021EP
21173680.612.05.2021EP
PCT/EP2021/05288505.02.2021EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SARBECOVIRUS BINDERS
(FR) LIANTS DE SARBECOVIRUS
Abstract
(EN) The invention relates to agents binding to sarbecoviruses of multiple clades and potently neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Application and uses of these agents are further part of this invention.
(FR) L'invention concerne des agents se liant aux sarbecovirus de multiples clades et neutralisant puissamment l'infection par le sarbecovirus, en particulier neutralisant l'infection par le SARS-CoV-1 et le SARS-CoV-2. Les agents se lient à un épitope unique du domaine de liaison au récepteur ACE2 (RBD) du sarbecovirus mais n'inhibent pas la liaison de l'ACE2 avec le RBD. L'invention concerne en outre l'application et les utilisations de ces agents.
Latest bibliographic data on file with the International Bureau